Navigation Links
Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Opportunities in the Generic Drug Landscape

PHILADELPHIA and LONDON, Jan. 26, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters today announced an agreement with Brazil's Institute for Applied Economic Research (IPEA). This partnership provides IPEA's Direction of Sectorial Studies and Policies for Innovation, Regulation and Infrastructure (DISET) branch with access to the Newport suite of products, supplying them with generic pharmaceutical intelligence as well as with tools for business development and the sourcing of global active pharmaceutical ingredients.

IPEA, a federal public foundation linked to the Strategic Affairs Secretariat of the Brazilian Presidency, provides technical and institutional support to the government for the development of public policies and development programs in Brazil. Within IPEA, DISET performs studies and evaluates public policies on science and technology, innovation, economic regulation, and antitrust.

DISET will use Newport to find new opportunities to improve Brazil's national pharmaceutical infrastructure – in research, development and manufacturing – as well as the quality of its active pharmaceutical ingredients. In addition to the extensive generic drug information available through the Newport suite of products, the group will have access to the Newport Generic Deals module, providing seamless integration of nearly 10,000 generic industry deals since 1999.

"We are enthusiastic about the Newport database," said Professor Eduardo Fiuza, member of the Board of Sector Studies for DISET. "I have never seen so much information about and capabilities for the generic drug market assembled in one single database. It will certainly speed up our data search and contribute to our extensive inquiry on the Brazilian pharmaceutical market. I hope that coverage of Brazilian indicators increases even further in the future."

"This is an exciting time in the evolution of Brazil's pharmaceutical development, and we are pleased to partner with DISET to ensure it meets its goals," said Jon Brett-Harris, executive vice president at Thomson Reuters. "Newport is an essential tool for uncovering new opportunities in the generic drug market, while the mergers and acquisitions data in our Deals module will help pave the way for further economic progress."

The Thomson Reuters Newport suite incorporates unique strategic intelligence and powerful competitive analysis. It integrates intelligence on more than 40,000 launched products containing over 10,000 different active ingredients and over 25,000 corporate groups. Newport Premium is the most advanced product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market. More information is available here.

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to     

SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets
2. BryanLGH Medical Center Implements Pharmacy Xpert from Thomson Reuters to Enhance Medication Management
3. Thomson Reuters-NPR Health Poll Finds Three in Four Americans Link Narcotic Pain Killers to Drug Addiction
4. Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange
5. Thomson Reuters - NPR Health Poll Finds Three-Quarters of Americans Support Government Insurance Subsidies for Birth Control Pills
6. Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands
7. Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
8. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
9. Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters
10. Thomson Reuters Unveils Pharmacy Xpert Solution to Improve Medication Management for Hospital Pharmacists
11. Thomson Reuters Releases iPhone Support for Clinical Xpert Navigator
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):